Skip to content
10-Q

Quarterly Report

ACRO BIOMEDICAL CO., LTD. ACBM

0001640334-25-001347

← back to feed
Filed
Aug 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Jul 23, 2025 60.04M sh
Shares Diluted Q2 2025 · Jun 30, 2025 60.04M sh
Shares Diluted Q2 2025 · Jun 30, 2025 60.04M sh
Shares Diluted Q2 2025 · Jun 30, 2024 60.04M sh
Shares Diluted Q2 2025 · Jun 30, 2024 60.04M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$116.52K
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$19.84K
Stockholders Equity Q2 2025 · Jun 30, 2025 −$317.52K
Stockholders Equity Q2 2025 · Mar 31, 2025 −$303.91K
Stockholders Equity Q2 2025 · Dec 31, 2024 −$294.97K
Stockholders Equity Q2 2025 · Jun 30, 2024 −$276.4K
Stockholders Equity Q2 2025 · Mar 31, 2024 −$267.31K
Stockholders Equity Q2 2025 · Dec 31, 2023 −$257.01K
Current Liabilities Q2 2025 · Jun 30, 2025 $370.8K
Current Liabilities Q2 2025 · Dec 31, 2024 $326.95K
Current Assets Q2 2025 · Jun 30, 2025 $39.63K
Current Assets Q2 2025 · Dec 31, 2024 $5.08K
Total Assets Q2 2025 · Jun 30, 2025 $53.28K
Total Assets Q2 2025 · Dec 31, 2024 $31.97K
Eps Diluted Q2 2025 · Jun 30, 2025 $0.00
Eps Diluted Q2 2025 · Jun 30, 2025 $0.00
Eps Diluted Q2 2025 · Jun 30, 2024 $0.00
Eps Diluted Q2 2025 · Jun 30, 2024 $0.00
Sga Expense Q2 2025 · Jun 30, 2025 $13.61K
Sga Expense Q2 2025 · Jun 30, 2025 $22.55K
Sga Expense Q2 2025 · Jun 30, 2024 $9.09K
Sga Expense Q2 2025 · Jun 30, 2024 $19.38K
Net Income Q2 2025 · Jun 30, 2025 −$15.56K
Net Income Q2 2025 · Jun 30, 2025 −$25.86K
Net Income Q2 2025 · Mar 31, 2025 −$10.3K
Net Income Q2 2025 · Jun 30, 2024 −$10.14K
Net Income Q2 2025 · Jun 30, 2024 −$21.4K
Net Income Q2 2025 · Mar 31, 2024 −$11.25K
Operating Income Q2 2025 · Jun 30, 2025 −$13.61K
Operating Income Q2 2025 · Jun 30, 2025 −$22.55K
Operating Income Q2 2025 · Jun 30, 2024 −$9.09K
Operating Income Q2 2025 · Jun 30, 2024 −$19.38K
Revenue Q2 2025 · Jun 30, 2025 $0
Revenue Q2 2025 · Jun 30, 2025 $0
Revenue Q2 2025 · Jun 30, 2024 $0
Revenue Q2 2025 · Jun 30, 2024 $0